Rami Manochakian: FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.

Edward Cliff: I’m delighted to share that I was selected to be an FDA American Association of Cancer Research Oncology Education Fellow for 2023-2024.

Bishal Gyawali: Kudos to the FDA for being proactive and swift in making withdrawal recommendations in recent years.

Vivek Subbiah: What a fantastic meeting packed with everything that’s needed for an early-phase drug development program.

W. Michael Korn: The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel.

Vivek Subbiah: Fantastic keynote lecture on “The FDA perspective on early phase pre-market dose optimization” by the amazing Dr. Paul Kluetz.

Kristina Jenei: This thread on drug shortages is better than most papers I’ve read about the subject.

Tatiana Prowell: The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology.

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 4

Ruben A. Mesa: Deeply excited by the Food and Drug Administration approval of Momelotinib for patients with myelofibrosis with anemia.